Patents by Inventor Tomoko Matsushima
Tomoko Matsushima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9146239Abstract: There is provided a method of judging a risk of cancer recurrence based on the activity value and expression level of the first CDK, the activity value and expression level of the second CDK, and the expression levels of uPA and PAI-1 and a computer program.Type: GrantFiled: November 20, 2012Date of Patent: September 29, 2015Assignee: SYSMEX CORPORATIONInventors: Hideki Ishihara, Tomoko Matsushima, Satoshi Nakayama, Manfred Schmitt, Marion Kiechle, Rupert Langer, Ulrike Schwarz-Boeger
-
Patent number: 8921114Abstract: A diagnosis support system for cancer is disclosed that comprises: a measurement value acquiring section for acquiring a measurement value of a first cancer patient; a sample data memory for storing sample data of a plurality of cancer patients different from the first patient; a reference range determination section for determining a reference range based on the measurement value of the first cancer patient; a display unit; and a display controller for controlling the display unit to display a diagnosis support screen showing the clinical information included in the sample data having measurement value within the reference range. A method of providing cancer diagnosis support information and a computer program product are also disclosed.Type: GrantFiled: August 25, 2008Date of Patent: December 30, 2014Assignee: Sysmex CorporationInventors: Hideki Ishihara, Tomoko Matsushima, Masaki Shibayama
-
Patent number: 8921057Abstract: A CDK profile including a ratio of specific activities of two cyclin dependent kinases closely correlates with the malignancy grade and the presence/absence of the sensitivity to an irritant such as an anticancer agent of a cancer tissue in clinical medicine. Therefore, the properties of a mammalian cell, such as malignancy grade, proliferation potency, sensitivity to an irritant such as an anticancer agent can be assessed based on its CDK profile or by comparing the result of a specific activity ratio of two CDKs with a predetermined threshold corresponding to the ratio. This sensitivity assessing method shows a high ratio of correct assessing results particularly in positive or sensitivity and is useful in predicting efficacy of chemotherapy using the anticancer agent.Type: GrantFiled: May 30, 2005Date of Patent: December 30, 2014Assignee: Sysmex CorporationInventors: Hideki Ishihara, Tomoko Matsushima, Yuko Kawasaki
-
Patent number: 8160821Abstract: A method of supporting a diagnosis of an effect of a treatment by using anthracycline anticancer drugs is disclosed. The method provides a new value for judging an effect, a judgment score, which is calculated based on expression levels and activity values of two cyclin dependent kinases (CDKs). The effect of the treatment by using anthracycline anticancer drugs is judged by comparing the judgment score with a predetermined threshold level.Type: GrantFiled: September 30, 2008Date of Patent: April 17, 2012Assignee: Sysmex CorporationInventors: Masaki Shibayama, Hideki Ishihara, Tomoko Matsushima, Shigehiro Numada
-
Patent number: 8131520Abstract: A device for supporting a diagnosis of a cancer which provides information useful to decide whether or not an anthracycline anticancer drug should be administered to a cancer patient to be examined is disclosed. Concretely, the device is composed to be able to acquire an activity and an expression of two cyclin dependent kinases (CDK) from a malignant tumor of a cancer patient to be examined, and to acquire a CDK parameters from both of two CDKs. Furthermore the device determines sample data comprising predetermined CDK parameter, and display information of determined sample data. According to the above component, user is easily able to know whether or not a cancer of a cancer patient, whose tumor is similar to the tumor of the cancer patient to be examined, has been recurred in spite of an administration of an anthracycline anticancer drug.Type: GrantFiled: October 1, 2008Date of Patent: March 6, 2012Assignee: Sysmex CorporationInventors: Hideki Ishihara, Tomoko Matsushima
-
Patent number: 8041514Abstract: A method for judging feature of malignant tumor is described. The method comprises obtaining step, first comparing step, second comparing step and judging step. The obtaining step comprises obtaining a first parameter based on activity and expression level of a first cyclin dependent kinase (first CDK) contained in a tumor cell of the malignant tumor, a second parameter based on activity and expression level of a second cyclin dependent kinase (second CDK) contained in the tumor cell, a third parameter based on the first parameter and the second parameter, and a fourth parameter based on expression level of a cyclin contained in the tumor cell. The first comparing step comprises comparing a first threshold value with the third parameter. The second comparing comprises comparing a second threshold value with the fourth parameter. The judging step comprises judging the feature of the malignant tumor based on the comparison results of the first comparing step and the second comparing step.Type: GrantFiled: February 27, 2007Date of Patent: October 18, 2011Assignee: Sysmex CorporationInventors: Satoshi Tanaka, Masaki Shibayama, Hideki Ishihara, Tomoko Matsushima, Aya Katayama, Yuko Kawasaki
-
Patent number: 8021831Abstract: The present invention provides a method for determining the chemosensitivity of a cancer cell to a taxane comprising assessing the effect of the taxane on the expression level or activity of one or more cell cycle molecules in a cancer cell. Such a method makes use of an automated analyzer system wherein cell cycle parameters (molecules) such as CDK1 kinase activity, CDK1 expression, CDK2 kinase activity, CDK2 expression, MAD2 expression, Cyclin B1, Cyclin E expression, p21 expression, and CDK6 expression; are assessed. The present invention further provides a method of obtaining a cell cycle profile of a cancer cell that is sensitive to a taxane.Type: GrantFiled: August 25, 2004Date of Patent: September 20, 2011Assignees: Board of Regents, The University of Texas System, Sysmex CorporationInventors: Naoto T. Ueno, Hideki Ishihara, Tamotsu Sudo, Tomoko Matsushima
-
Patent number: 8014960Abstract: A method of supporting a diagnosis of a risk of cancer recurrence is disclosed. The method provides a new determining value a recurrence risk score (RRS) which is calculated based on expression levels and activity values of two cyclin dependent kinases (CDKs). The risk of cancer recurrence is judged by comparing the RRS with a predetermined threshold level for RRS.Type: GrantFiled: September 30, 2008Date of Patent: September 6, 2011Assignee: Sysmex CorporationInventors: Masaki Shibayama, Hideki Ishihara, Tomoko Matsushima, Shigehiro Numada
-
Patent number: 7957910Abstract: A method for predicting an effectiveness of chemotherapy is described. The method comprises a comparing step and a predicting step. The comparing step is a step of comparing a threshold value with a parameter of a cyclin dependent kinase (CDK) included in a sample containing a tumor cell obtained from a human patient. The predicting step is a step of predicting the effectiveness based on a comparison result of the comparing step. Above stated parameter is selected from the group consisting of an activity, an expression level, and a ratio of activity to expression level.Type: GrantFiled: January 12, 2006Date of Patent: June 7, 2011Assignee: Sysmex CorporationInventors: Yasuhiro Torikoshi, Yuko Kawasaki, Satoshi Nakayama, Hideki Ishihara, Tomoko Matsushima
-
Patent number: 7682785Abstract: The present invention provides a method for predicting an effectiveness of chemotherapy using an anticancer agent with high probability. The effectiveness is predicted based on a comparison of a parameter relating to CDK and/or CDK inhibitor in a tumor cell specimen obtained from a patient, with a corresponding threshold value to the parameter. The patient to be subjected this sensitivity prediction test of an anticancer agent is administered with the anticancer agent prior to removal of the tumor cell. The threshold is predetermined based on data of correlation between the selected parameter and anticancer agent therapy results obtained from a number of patients actually performed the therapy. Accordingly, the predicting method can provide information useful for determining whether to perform the chemotherapy to individual patients.Type: GrantFiled: June 27, 2006Date of Patent: March 23, 2010Assignee: Sysmex CorporationInventors: Tomoko Matsushima, Yuko Kawasaki, Hideki Ishihara
-
Publication number: 20090246809Abstract: A method of supporting a diagnosis of a risk of cancer recurrence is disclosed. The method provides a new determining value a recurrence risk score (RRS) which is calculated based on expression levels and activity values of two cyclin dependent kinases (CDKs). The risk of cancer recurrence is judged by comparing the RRS with a predetermined threshold level for RRS.Type: ApplicationFiled: September 30, 2008Publication date: October 1, 2009Applicant: SYSMEX CORPORATIONInventors: Masaki Shibayama, Hideki Ishihara, Tomoko Matsushima, Shigehiro Numada
-
Publication number: 20090248316Abstract: A method of supporting a diagnosis of an effect of a treatment by using anthracycline anticancer drugs is disclosed. The method provides a new value for judging an effect, a judgment score, which is calculated based on expression levels and activity values of two cyclin dependent kinases (CDKs). The effect of the treatment by using anthracycline anticancer drugs is judged by comparing the judgment score with a predetermined threshold level.Type: ApplicationFiled: September 30, 2008Publication date: October 1, 2009Applicant: SYSMEX CORPORATIONInventors: Masaki Shibayama, Hideki Ishihara, Tomoko Matsushima, Shigehiro Numada
-
Publication number: 20090105960Abstract: A device for supporting a diagnosis of a cancer which provides information useful to decide whether or not an anthracycline anticancer drug should be administered to a cancer patient to be examined is disclosed. Concretely, the device is composed to be able to acquire an activity and an expression of two cyclin dependent kinases (CDK) from a malignant tumor of a cancer patient to be examined, and to acquire a CDK parameters from both of two CDKs. Furthermore the device determines sample data comprising predetermined CDK parameter, and display information of determined sample data. According to the above component, user is easily able to know whether or not a cancer of a cancer patient, whose tumor is similar to the tumor of the cancer patient to be examined, has been recurred in spite of an administration of an anthracycline anticancer drug.Type: ApplicationFiled: October 1, 2008Publication date: April 23, 2009Inventors: Hideki Ishihara, Tomoko Matsushima
-
Publication number: 20090054739Abstract: A diagnosis support system for cancer is disclosed that comprises: a measurement value acquiring section for acquiring a measurement value of a first cancer patient; a sample data memory for storing sample data of a plurality of cancer patients different from the first patient; a reference range determination section for determining a reference range based on the measurement value of the first cancer patient; a display unit; and a display controller for controlling the display unit to display a diagnosis support screen showing the clinical information included in the sample data having measurement value within the reference range. A method of providing cancer diagnosis support information and a computer program product are also disclosed.Type: ApplicationFiled: August 25, 2008Publication date: February 26, 2009Applicant: SYSMEX CORPORATIONInventors: Hideki ISHIHARA, Tomoko Matsushima, Masaki Shibayama
-
Publication number: 20070231837Abstract: A CDK profile including a ratio of specific activities of two cyclin dependent kinases closely correlates with the malignancy grade and the presence/absence of the sensitivity to an irritant such as an anticancer agent of a cancer tissue in clinical medicine. Therefore, the properties of a mammalian cell, such as malignancy grade, proliferation potency, sensitivity to an irritant such as an anticancer agent can be assessed based on its CDK profile or by comparing the result of a specific activity ratio of two CDKs with a predetermined threshold corresponding to the ratio. This sensitivity assessing method shows a high ratio of correct assessing results particularly in positive or sensitivity and is useful in predicting efficacy of chemotherapy using the anticancer agent.Type: ApplicationFiled: May 30, 2005Publication date: October 4, 2007Inventors: Hideki Ishihara, Tomoko Matsushima, Yuko Kawasaki
-
Publication number: 20070202555Abstract: A method for judging feature of malignant tumor is described. The method comprises obtaining step, first comparing step, second comparing step and judging step. The obtaining step comprises obtaining a first parameter based on activity and expression level of a first cyclin dependent kinase (first CDK) contained in a tumor cell of the malignant tumor, a second parameter based on activity and expression level of a second cyclin dependent kinase (second CDK) contained in the tumor cell, a third parameter based on the first parameter and the second parameter, and a fourth parameter based on expression level of a cyclin contained in the tumor cell. The first comparing step comprises comparing a first threshold value with the third parameter. The second comparing comprises comparing a second threshold value with the fourth parameter. The judging step comprises judging the feature of the malignant tumor based on the comparison results of the first comparing step and the second comparing step.Type: ApplicationFiled: February 27, 2007Publication date: August 30, 2007Applicant: SYSMEX CORPORATIONInventors: Satoshi Tanaka, Masaki Shibayama, Hideki Ishihara, Tomoko Matsushima, Aya Katayama, Yuko Kawasaki
-
Publication number: 20070003964Abstract: The present invention provides a method for predicting an effectiveness of chemotherapy using an anticancer agent with high probability. The effectiveness is predicted based on a comparison of a parameter relating to CDK and/or CDK inhibitor in a tumor cell specimen obtained from a patient, with a corresponding threshold value to the parameter. The patient to be subjected this sensitivity prediction test of an anticancer agent is administered with the anticancer agent prior to removal of the tumor cell. The threshold is predetermined based on data of correlation between the selected parameter and anticancer agent therapy results obtained from a number of patients actually performed the therapy. Accordingly, the predicting method can provide information useful for determining whether to perform the chemotherapy to individual patients.Type: ApplicationFiled: June 27, 2006Publication date: January 4, 2007Inventors: Tomoko Matsushima, Yuko Kawasaki, Hideki Ishihara
-
Publication number: 20060292645Abstract: A method of measuring the activity of a kinase to which imatinib mesylate can bind is described. In the method, a kinase contained in a sample, to which imatinib mesylate can bind, a substrate for the kinase, and ATP are mixed. A phosphate group of ATP is thereby transferred to a tyrosine residue of the substrate by the action of the kinase. After a labeled substance capable of binding is bound to the substrate having the phosphate group transferred thereto, a signal emitted by the labeled substance is detected. On the basis of this detection result, the activity of the kinase is calculated.Type: ApplicationFiled: June 23, 2006Publication date: December 28, 2006Inventors: Tomoko Matsushima, Hideki Ishihara
-
Publication number: 20060173632Abstract: A method for predicting an effectiveness of chemotherapy is described. The method comprises a comparing step and a predicting step. The comparing step is a step of comparing a threshold value with a parameter of a cyclin dependent kinase (CDK) included in a sample containing a tumor cell obtained from a human patient. The predicting step is a step of predicting the effectiveness based on a comparison result of said comparing step. Above stated parameter is selected from the group consisting of an activity, an expression level, and a ratio of activity to expression level.Type: ApplicationFiled: January 12, 2006Publication date: August 3, 2006Inventors: Yasuhiro Torikoshi, Yuko Kawasaki, Satoshi Nakayama, Hideki Ishihara, Tomoko Matsushima
-
Publication number: 20050131057Abstract: The present invention provides a method for determining the chemosensitivity of a cancer cell to a taxane comprising assessing the effect of the taxane on the expression level or activity of one or more cell cycle molecules in a cancer cell. Such a method makes use of an automated analyzer system wherein cell cycle parameters (molecules) such as CDK1 kinase activity, CDK1 expression, CDK2 kinase activity, CDK2 expression, MAD2 expression, Cyclin B1, Cyclin E expression, p21 expression, and CDK6 expression; are assessed. The present invention further provides a method of obtaining a cell cycle profile of a cancer cell that is sensitive to a taxane.Type: ApplicationFiled: August 25, 2004Publication date: June 16, 2005Inventors: Naoto Ueno, Hideki Ishihara, Tamotsu Sudo, Tomoko Matsushima